NASDAQ$BEAM
Beam Therapeutics Inc. · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Beam Therapeutics reported its first quarter 2025 financial results, highlighting progress in its clinical programs and a strong financial position.
Beam Therapeutics had a strong first quarter in 2025, marked by significant clinical advancements including the first patient dosed in the BEAM-301 trial and continued progress in the BEAM-302 and BEAM-101 programs. The company also strengthened its financial foundation with a $500 million financing, extending its cash runway into 2028.
- First patient dosed in the Phase 1/2 study of BEAM-301 for Glycogen Storage Disease Type Ia, marking the company's second clinical-stage in vivo editing program.
- Updated data from the BEACON Phase 1/2 clinical trial of BEAM-101 for sickle cell disease accepted for presentation at the European Hematology Association 2025 Congress in June.
- Initiated dosing of the fourth cohort in Part A of the Phase 1/2 trial for BEAM-302 in Alpha-1 Antitrypsin Deficiency and received U.S. IND clearance.
- Ended the first quarter of 2025 with $1.2 billion in cash, cash equivalents, and marketable securities, including net proceeds from a $500 million financing, with a cash runway expected to support operating plans into 2028.
Headline financials
Revenue & EPS history
Beam Therapeutics · Revenue · Quarterly
$7.47M
Revenue by segment
Beam Therapeutics · $6K total across 1 segment · Q2 2021
- License & collaboration revenue$6K—100.0%
Forward guidance
Beam Therapeutics expects to continue advancing its clinical programs and maintain a strong financial position, with cash runway into 2028.
Tailwinds
- Plans to continue the dose-escalation portion of Part A of the BEAM-302 Phase 1/2 clinical trial and expects to report further data at a medical conference in the second half of 2025.
- Plans to dose the first patient in Part B of the BEAM-302 Phase 1/2 clinical trial, which will include AATD patients with mild to moderate liver disease, in the second half of 2025.
- Plans to continue dosing in the Phase 1/2 clinical trial of BEAM-301 in GSDIa.
- Expects to dose 30 patients in the BEACON Phase 1/2 clinical trial of BEAM-101 in adults with severe SCD by mid-2025.
- Expects to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, the ESCAPE monoclonal antibody, by the end of 2025.
Headwinds
- Clinical trials may take longer or cost more than planned.
- Uncertainty that product candidates will receive necessary regulatory approval.
- Preclinical and preliminary clinical data may not be predictive of future results.
- Product candidates or delivery modalities may cause serious adverse events.
- Manufacturing or supply interruptions or failures may occur.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.6%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+21.8%
Q4 2023
Best reaction
-11.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -2.4% | -9.3% | |
| Q4 2025 | +14.1% | +0.5% | -16.6% | |
| Q3 2025 | -6.4% | -8.4% | +19.2% | |
| Q1 2025 | +3.9% | -0.2% | -1.1% | |
| Q4 2024 | -3.1% | -14.5% | -27.9% | |
| Q3 2024 | +9.3% | +11.1% | +3.9% | |
| Q2 2024 | -4.5% | -4.5% | -5.6% | |
| Q1 2024 | -2.4% | -6.7% | +5.7% | |
| Q4 2023 | +21.8% | +11.3% | -7.7% | |
| Q3 2023 | -11.1% | -12.2% | +5.6% | |
| Q2 2023 | +2.2% | +0.0% | -1.5% | |
| Q1 2023 | +1.9% | +4.3% | -6.7% | |
| Q4 2022 | -1.3% | +0.3% | -22.7% | |
| Q3 2022 | -10.3% | +19.0% | +3.0% | |
| Q2 2022 | +3.2% | +8.5% | -10.4% | |
| Q1 2022 | +0.3% | -0.6% | +12.6% | |
| Q4 2021 | -1.7% | -14.3% | -20.5% | |
| Q3 2021 | +9.1% | +2.9% | -11.4% | |
| Q2 2021 | +1.0% | -5.6% | +1.0% | |
| Q1 2021 | +4.3% | +12.2% | +37.1% | |
| Q4 2020 | -4.4% | -5.6% | -22.3% | |
| Q3 2020 | +2.5% | -1.4% | +109.9% | |
| Q2 2020 | -5.1% | -3.5% | +8.6% | |
| Q1 2020 | +3.3% | +3.4% | +23.1% | |
| Q4 2019 | +3.3% | +3.4% | +23.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro